Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA)
CUSIP: 29384C108
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 38,346,880
- Total 13F shares
- 28,408,651
- Share change
- -1,320,277
- Total reported value
- $164,766,270
- Put/Call ratio
- 102%
- Price per share
- $5.80
- Number of holders
- 114
- Value change
- -$9,410,304
- Number of buys
- 72
- Number of sells
- 44
Quarterly Holders Quick Answers
What is CUSIP 29384C108?
CUSIP 29384C108 identifies TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29384C108:
Top shareholders of TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,381,062
|
$88,628,884 | — | 10 Dec 2024 | |
| MPM BIOVENTURES 2018, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,381,062
|
$88,628,884 | — | 10 Dec 2024 | |
| ROCHE HOLDING LTD |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,813,525
|
$44,988,265 | — | 02 Nov 2021 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
13%
|
4,865,819
|
$32,698,304 | — | 30 Jun 2025 | |
| Redmile Group, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,954,420
|
$31,251,176 | — | 02 Nov 2021 | |
| MPM ASSET MANAGEMENT LLC |
13F
|
Company |
11%
|
4,381,062
|
$29,440,737 | — | 30 Jun 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
11%
|
4,308,379
|
$28,952,307 | — | 30 Jun 2025 | |
| ROCHE FINANCE LTD |
13D/G
|
— |
6.9%
|
2,569,115
|
$23,019,270 | $0 | 31 Dec 2024 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
5.3%
|
1,974,452
|
$17,691,090 | $0 | 31 Dec 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
|
Company · T. Rowe Price Associates, Inc. |
0.9%
from 13D/G
|
2,567,478
|
$17,255,000 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.2%
|
1,604,860
|
$10,784,659 | — | 30 Jun 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
|
Company |
4%
from 13D/G
|
1,521,281
|
$10,207,796 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.8%
|
1,060,716
|
$7,128,011 | — | 30 Jun 2025 | |
| StepStone Group LP |
13F
|
Company |
2%
|
761,277
|
$5,115,781 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
631,554
|
$4,244,897 | — | 30 Jun 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.5%
|
584,955
|
$3,930,898 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
1.3%
|
496,129
|
$3,333,988 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.3%
|
495,862
|
$3,332,193 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.1%
|
423,985
|
$2,849,839 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.99%
|
379,500
|
$2,550,240 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.78%
|
300,321
|
$2,018,157 | — | 30 Jun 2025 | |
| Peter S. Kim |
3/4/5
|
Director |
—
mixed-class rows
|
136,412
mixed-class rows
|
$1,712,677 | — | 11 Jun 2025 | |
| ROYCE & ASSOCIATES LP |
13F
|
Company |
0.58%
|
223,251
|
$1,500,247 | — | 30 Jun 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.58%
|
220,736
|
$1,483,346 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.53%
|
203,693
|
$1,368,817 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.44%
|
170,322
|
$1,144,564 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.43%
|
163,097
|
$1,096,012 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.35%
|
133,730
|
$898,666 | — | 30 Jun 2025 | |
| MOORE CAPITAL MANAGEMENT, LP |
13F
|
Company |
0.27%
|
105,000
|
$705,600 | — | 30 Jun 2025 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
0.27%
|
102,008
|
$685,494 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.26%
|
100,357
|
$674,399 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.26%
|
98,028
|
$658,748 | — | 30 Jun 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.25%
|
96,686
|
$649,730 | — | 30 Jun 2025 | |
| Nerissa Kreher |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
61,537
mixed-class rows
|
$640,192 | — | 01 Sep 2023 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.23%
|
87,387
|
$587,241 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.22%
|
84,150
|
$565,490 | — | 30 Jun 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.2%
|
75,120
|
$504,806 | — | 30 Jun 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.2%
|
75,094
|
$504,632 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.15%
|
58,082
|
$390,312 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.15%
|
56,416
|
$379,116 | — | 30 Jun 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.15%
|
55,824
|
$375,137 | — | 30 Jun 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.13%
|
51,158
|
$343,782 | — | 30 Jun 2025 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.13%
|
49,082
|
$329,831 | — | 30 Jun 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.12%
|
47,788
|
$321,135 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.12%
|
45,806
|
$306,000 | — | 30 Jun 2025 | |
| STRS OHIO |
13F
|
Company |
0.12%
|
45,000
|
$302,400 | — | 30 Jun 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.12%
|
44,946
|
$302,037 | — | 30 Jun 2025 | |
| LOS ANGELES CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.12%
|
44,632
|
$299,927 | — | 30 Jun 2025 | |
| AlphaQuest LLC |
13F
|
Company |
0.1%
|
39,625
|
$266,280 | — | 30 Jun 2025 | |
| MARTINGALE ASSET MANAGEMENT L P |
13F
|
Company |
0.1%
|
39,463
|
$265,193 | — | 30 Jun 2025 |
Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q3 2025
As of 30 Sep 2025,
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) was held by
114 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,408,651 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, MPM ASSET MANAGEMENT LLC, 5AM Venture Management, LLC, BlackRock, Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, MILLENNIUM MANAGEMENT LLC, StepStone Group LP, GEODE CAPITAL MANAGEMENT, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
114
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
105
Q3 2025 holders
114
Holder diff
9
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.